Sponsor: 
Merck Sharp & Dohme (Australia)
Administration route: 
Subcutaneous injection
Vaccine group: 
Monovalent vaccines

Registered for use in people aged ≥12 months.

Monovalent varicella vaccine

Lyophilised powder in a monodose vial with a pre-filled diluent syringe.

Each 0.5 mL reconstituted dose contains:

  • ≥1350 plaque-forming units of live attenuated varicella-zoster virus (Oka/Merck strain)
  • 18 mg sucrose
  • 8.9 mg hydrolysed porcine gelatin
  • 3.6 mg urea
  • 0.36 mg monosodium glutamate
  • residual components of MRC-5 cells

Also contains traces of:

  • neomycin
  • bovine serum

For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018